RecruitingPHASE1, PHASE2NCT05791409

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Intervention: Epcoritamab(drug)
Enrollment: 112 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2032

Study locations (24)

BE-Antwerpen-ZNASTUIVENBERG, Antwerp, Belgium
BE-Roeselare-AZDELTA, Roeselare, Belgium
DK-Aalborg-ALBOGUH, Aalborg, Denmark
DK-Copenhagen-RIGSHOSPITALET, Copenhagen, Denmark
DK-Odense-OUH, Odense, Denmark
DE-Berlin-HELIOSBERLINBUCH, Berlin, Germany
DE-Köln-UKKOELN, Cologne, Germany
DE-Freiburg-UNIKLINIKFREIBURG, Freiburg im Breisgau, Germany
DE-Greifswald-UNIGREIFSWALD, Greifswald, Germany
DE-Munster-GEMEINSCHAFTSPRAXIS, Münster, Germany
DE-Stuttgart-RBK, Stuttgart, Germany
DE-Ulm-UNIKLINKULM, Ulm, Germany
NL-Den Bosch-JBZ, 's-Hertogenbosch, Netherlands
NL-Alkmaar-NWZ, Alkmaar, Netherlands
NL-Amersfoort-MEANDERMC, Amersfoort, Netherlands
+9 more locations on ClinicalTrials.gov

Collaborators

Nordic CLL Study Group · German CLL Study Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05791409 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials